| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8715711 | Journal of Dermatological Science | 2018 | 7 Pages |
Abstract
In our study, the response ratio to ipilimumab after nivolumab was unsatisfactory and associated with a high frequency of severe irAEs. As there are few second-line treatment options for patients with BRAF wild-type advanced melanoma after nivolumab failure, patients should be closely monitored if ipilimumab is initiated.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Takeru Funakoshi, Hiroshi Uchi, Taku Fujimura, Shigeto Matsushita, Hiroo Hata, Hisako Okuhira, Ryota Tanaka, Kojiro Nagai, Yoshihiro Ishida, Yoshio Nakamura, Sadanori Furudate, Kentaro Yamamura,